EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes

Iriagbonse I Osaigbovo iD, Bassey E Ekeng iD, Adeyinka A Davies iD, Rita O Oladele iD

Mycoses · 2023

DOI: 10.1111/myc.13581 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Mycoses, 2023. Verfasst von Iriagbonse I Osaigbovo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, School of Medicine, College of Medical Sciences, University of Benin, Benin City, Nigeria. Hauptthemen laut MEDLINE: Mucormycosis, COVID-19, Mucorales. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucorales fungi cause mucormycosis, an invasive and rapidly progressive disease which increasingly affects mostly immunocompromised but also immunocompetent individuals. The objective of this study was to highlight the epidemiology, diagnostic modalities, treatment and overall survival of mucormycosis in Africa. We searched for relevant publications in PubMed, Google Scholar and African Journal Online databases covering the period 1960–2022. A total of 147 articles were identified, of which 66 were included in the review, detailing 408 individual cases from 12 African countries; 330 (80.9%) from North Africa, 63 (15.4%) from Southern Africa, seven (1.7%) from East Africa, seven (1.7%) from West Africa and a single case (0.2%) from Central Africa. The most frequently described clinical forms were rhino‐orbital‐cerebral ( n = 307, 75.2%) and gastrointestinal ( n = 51, 12.5%). Diabetes mellitus, COVID‐19, malignancies and neutropaenia were the commonest underlying risks in 203 (49.8%), 101 (24.8%), 65 (15.9%) and 53 (13.0%) cases respectively. Most cases, 296 (72.5%) were diagnosed by histopathology. Fungal aetiology was identified in 38 (9.3%), of which the commonest was Rhizopus oryzae/arrhizus (27/38, 71.1%). Of the 408 cases, 334 (81.9%) patients received antifungal therapy, while 244 (59.8%) had surgery. In cases with a specified outcome, survival rate was 59.1% (228/386). Based on case reporting, a substantial burden of mucormycosis occurs in North Africa but the disease is rarely reported in most of the sub‐Saharan region. Establishing a comprehensive registry for standardised data collection could improve understanding of the epidemiology of mucormycosis in the region.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucormycosisCOVID-19MucoralesHumansTreatment OutcomeAfricaRhizopus oryzaeAntifungal AgentsCOVID-19 Testing

Stichwörter der Autor:innen

AfricaMucormycosisdiabetes mellitusfungi

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Department of Medical Microbiology, School of Medicine, College of Medical Sciences, University of Benin, Benin City, Nigeria.
  • Medical Mycology Society of Nigeria, Lagos, Nigeria.
  • Department of Medical Microbiology and Parasitology, University of Calabar Teaching Hospital, Calabar, Nigeria.
  • Department of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.
  • Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.

ORCID-Profile: Iriagbonse I Osaigbovo, Bassey E Ekeng, Adeyinka A Davies, Rita O Oladele

Zitieren

APA

Osaigbovo, I. I., Ekeng, B. E., Davies, A. A., & Oladele, R. O. (2023). Mucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes. Mycoses. https://doi.org/10.1111/myc.13581

Vancouver

Osaigbovo II, Ekeng BE, Davies AA, Oladele RO. Mucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes. Mycoses. 2023. doi:10.1111/myc.13581

BibTeX
@article{Osaigbovo2023,
  author = {Osaigbovo, Iriagbonse I and Ekeng, Bassey E and Davies, Adeyinka A and Oladele, Rita O},
  title = {Mucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes},
  journal = {Mycoses},
  year = {2023},
  doi = {10.1111/myc.13581}
}
Kostenlos starten →